| Company Name: | E-Z-EM, Incorporated | | Ticker Symbol: | EZEM | | | WWW Address: | www.ezem.com | | CEO: | Anthony A. Lombardo | | No. of Employees: | 590 | | Common Issue Type: | CS | | Business Description: | The Company develops, manufactures and markets medical diagnostic products used for computed tomography and magnetic resonance imaging, colorectal cancer screening, evaluation of swallowing disorders and testing for other diseases.
|
| | | Industry Information: | DRUGS - Diagnostic Support [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 21.0 |  0.0 | - | - | 0 | 21.00 | 20.97 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 233.1 | 11.1 | 0.91 | 0.77 | 0.00 | 26.9 | 0.0 | 21.00 - 11.68 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 21.00 | $ | | PE Ratio - LTM | 26.9 | |
| Market Capitalisation | 232.8 | mil |
| Latest Shares Outstanding | 11.1 | mil |
| Earnings pS (EPS) | 0.77 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 233,627 | $ |
| Effective Tax Rate | 31.8 | % |
| Float | 10.0 | mil |
| Float as % of Shares Outstanding | 90.3 | % |
| Foreign Sales | 26 | mil |
| Domestic Sales | 112 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 31.70 | % |
| Research & Devlopment (R&D) as % of Revenue | 4.30 | % |
| Gross Profit Margin | 46.5 | % |
| EBITDA Margin | 10.4 | % |
| Pre-Tax Profit Margin | 8.2 | % |
| Assets Turnover | 1.1 | % |
| Return on Assets (ROA) | 6.0 | % |
| Return on Equity (ROE) | 7.1 | % |
| Return on Capital Invested (ROCI) | 7.1 | % |
| Current Ratio | 6.1 | |
| Leverage Ratio (Assets/Equity) | 1.2 | |
| Interest Cover | 42.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 8.28 | $ |
| Cash pS | 0.89 | $ |
| Book-Value pS | 10.96 | $ |
| Tangible Book-Value pS | 10.69 | $ |
| Cash Flow pS | 1.10 | $ |
| Free Cash Flow pS | -0.11 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 1.92 | |
| Price/Tangible Book Ratio | 1.96 | |
| Price/Cash Flow | 19.1 | |
| Price/Free Cash Flow | -190.9 | |
| P/E as % of Industry Group | 117.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | Cash Payment |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.7 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 17.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.1 | 96 | 274 | 766 |
| 4 Weeks | 21.00 | 20.02 | 20.84 | 0.8 | 95 | 348 | 5,919 |
| 13 Weeks | 21.00 | 20.02 | 20.66 | 1.6 | 105 | 571 | 34,250 |
| 26 Weeks | 21.00 | 14.94 | 19.52 | 7.6 | 123 | 710 | 86,559 |
| 52 Weeks | 21.00 | 11.68 | 16.64 | 26.2 | 133 | 521 | 129,647 |
| YTD | 21.00 | 20.02 | - | 1.3 | 109 | 558 | 35,152 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 20.97 | 20.95 | 20.79 | 19.40 | 18.20 | 0.91 | 1.53 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 1.13 | 5.1 | 3.94 |
| Income | 27.02 | 72.3 | 4.54 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -1.74 | NA | 7.05 |
| R&D | -3.24 | NA | -3.38 |
| Normalized Inc. | 25.77 | NA | 0.18 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 13.3 | 27.7 | -0.4 |
| Earnings % | 1.2 | 53.0 | -12.5 |
| EPS % | 0.0 | 56.3 | -12.5 |
| EPS $ | 0.00 | 0.09 | -0.11 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 64.50 |
| Current Ratio | 6.1 |
| Quick Ratio (Acid Test) | 4.0 |
| Liquidity Ratio (Cash) | 2.57 |
| Receivables Turnover | 6.1 |
| Average Collection Period | 59 |
| Working Capital/Equity | 76.3 |
| Working Capital pS | 7.93 |
| Cash-Flow pS | 1.09 |
| Free Cash-Flow pS | 0.05 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 8.86 |
| Financial Leverage Ratio (Assets/Equity) | 1.2 |
| Debt Ratio | 15.5 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 3.3 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 39.6 |
| Interest/Capital Invested | 0.28 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 4.19 |
| Tobin's Q Ratio | 1.73 |
| Current P/E Ratio - LTM | 26.90 |
| Enterprise Value (EV)/EBITDA | 14.25 |
| Enterprise Value (EV)/Free Cash Flow | 569.68 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 1.96 |
| Price/Book Ratio - LTM | 1.92 |
| Price/Cash Flow Ratio | 19.1 |
| Price/Free Cash Flow Ratio - LTM | -190.9 |
| Price/Sales Ratio | 1.58 |
| P/E Ratio (1 month ago) - LTM | 26.6 |
| P/E Ratio (26 weeks ago) - LTM | 25.4 |
| P/E Ratio (52 weeks ago) - LTM | 20.5 |
| 5-Y High P/E Ratio | 42.1 |
| 5-Y Low P/E Ratio | 12.9 |
| 5-Y Average P/E Ratio | 25.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 108 |
| P/E as % of Industry Group | 117.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 24.7 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 1.57 |
| Tangible Book Value pS - LTM | 10.69 |
| Book Value pS - LTM | 10.96 |
| Capital Invested pS | 10.29 |
| Cash pS - LTM | 0.89 |
| Cash Flow pS - LTM | 1.10 |
| Free Cash Flow pS - LTM | -0.11 |
| Earnings pS (EPS) | 0.77 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 0.42 |
| Free Cash Flow Margin 5YEAR AVG | -0.76 |
| Net Profit Margin | 6.2 |
| Net Profit Margin - 5YEAR AVRG. | 5.2 |
| Equity Productivity | 1.21 |
| Return on Equity (ROE) | 7.5 |
| Return on Equity (ROE) - 5YEAR AVRG. | 6.9 |
| Capital Invested Productivity | 1.21 |
| Return on Capital Invested (ROCI) | 7.5 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 6.8 |
| Assets Productivity | 1.10 |
| Return on Assets (ROA) | 6.3 |
| Return on Assets (ROA) - 5YEAR AVRG. | 5.6 |
| Gross Profit Margin | 46.5 |
| Gross Profit Margin - 5YEAR AVRG. | 46.2 |
| EBITDA Margin - LTM | 10.4 |
| EBIT Margin - LTM | 8.4 |
| Pre-Tax Profit Margin | 9.1 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 6.6 |
| Effective Tax Rate | 31.8 |
| Effective Tax Rate - 5YEAR AVRG. | 24.2 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 204 |
| Revenue per Employee | 233,627 |
| Net Income per Employee | 14,480 |
| Average Collection Period | 64 |
| Receivables Turnover | 6.1 |
| Day's Inventory Turnover Ratio | 140 |
| Inventory Turnover | 2.6 |
| Inventory/Sales | 21.6 |
| Accounts Payble/Sales | 5.49 |
| Assets/Revenue | 0.91 |
| Net Working Capital Turnover | 1.58 |
| Fixed Assets Turnover | 4.49 |
| Total Assets Turnover | 1.1 |
| Revenue per $ Cash | 17.15 |
| Revenue per $ Plant | 8.17 |
| Revenue per $ Common Equity | 1.21 |
| Revenue per $ Capital Invested | 1.21 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 32.1 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 32.8 |
| Research & Devlopment (R&D) as % of Revenue | 4.1 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 4.1 |
|
|  
|
| |
 |  |